文献速递肝病消化道肿瘤与早癌

意大利肝癌预后系统对肝细胞癌患者的外部验证:一项多中心队列研究

External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study.
PubMed 文献 · Hepatology · 2018-04-19

研究在27家意大利机构连续纳入1508例肝硬化合并新发肝细胞癌患者,外部验证意大利肝癌(ITA.LI.CA)预后系统的预测能力,并与巴塞罗那临床肝癌系统等比较。中位随访44个月,ITA.LI.CA肿瘤分期0期246例、A期472例、B1/3期657例、C期133例。ITA.LI.CA预后系统判别能力最佳(C指数=0.77),按治愈或姑息治疗分层后仍优于其他系统。

要点

  • 研究纳入27家意大利机构的1508例肝硬化合并新发肝细胞癌患者,中位随访44个月。
  • ITA.LI.CA预后系统判别能力最佳,C指数=0.77,优于其他多维度预后系统。
  • 按治愈或姑息治疗分层后,ITA.LI.CA系统的优势仍得到确认。

核心结论

  • 这是首个在西方新发肝细胞癌患者大队列中独立验证ITA.LI.CA预后系统的研究,该系统判别能力优于其他多维度预后系统,按治愈或姑息治疗分层后仍成立。

研究设计与样本

  • 多中心队列研究,2008年9月至2016年4月在27家意大利机构连续纳入1508例肝硬化合并新发肝细胞癌患者,中位年龄71岁,以男性及丙型肝炎病毒携带者为主。

主要发现

  • 中位随访44个月(四分位距23-63个月),中位总生存期34个月(四分位距13-82个月)。
  • 按ITA.LI.CA肿瘤分期,0期246例、A期472例、B1/3期657例、C期133例。
  • ITA.LI.CA预后系统判别能力最佳,C指数=0.77,梯度单调性优于其他系统,按治愈或姑息治疗分层后优势仍被确认。

关键数值与推荐

  • 采用Harrell C指数、赤池信息准则和似然比检验比较各系统预测能力。
  • 比较的预后系统包括巴塞罗那临床肝癌系统、ITA.LI.CA预后系统、香港肝癌系统、意大利肝癌计划、日本整合系统及门诊肝细胞癌患者生存估计模型。

临床怎么用

  • 作者认为该新系统似乎尤其适用于临床实践中预测肝细胞癌患者的个体预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Several staging systems for hepatocellular carcinoma (HCC) have been developed. The Barcelona Clinic Liver Cancer staging system is considered the best in predicting survival, although limitations have emerged. Recently, the Italian Liver Cancer (ITA.LI.CA) prognostic system, integrating ITA.LI.CA tumor staging (stages 0, A, B1-3, C) with the Child-Turcotte-Pugh score, Eastern Cooperative Oncology Group performance status, and alpha-fetoprotein with a strong ability to predict survival, was proposed. The aim of our study was to provide an external validation of the ITA.LI.CA system in an independent real-life occidental cohort of HCCs. From September 2008 to April 2016, 1,508 patients with cirrhosis and incident HCC were consecutively enrolled in 27 Italian institutions. Clinical, tumor, and treatment-related variables were collected, and patients were stratified according to scores of the Barcelona Clinic Liver Cancer system, ITA.LI.CA prognostic system, Hong Kong Liver Cancer system, Cancer of the Liver Italian Program, Japanese Integrated System, and model to estimate survival in ambulatory patients with hepatocellular carcinoma. Harrell's C-index, Akaike information criterion, and likelihood-ratio test were used to compare the predictive ability of the different systems. A subgroup analysis for treatment category (curative versus palliative) was performed. Median follow-up was 44 months (interquartile range, 23-63 months), and median overall survival was 34 months (interquartile range, 13-82 months). Median age was 71 years, and patients were mainly male individuals and hepatitis C virus carriers. According to ITA.LI.CA tumor staging, 246 patients were in stage 0, 472 were in stage A, 657 were in stages B1/3, and 133 were in stage C. The ITA.LI.CA prognostic system showed the best discriminatory ability (C-index = 0.77) and monotonicity of gradients compared to other systems, and its superiority was also confirmed after stratification for treatment strategy. CONCLUSION: This is the first study that independently validated the ITA.LI.CA prognostic system in a large cohort of Western patients with incident HCCs. The ITA.LI.CA system performed better than other multidimensional prognostic systems, even after stratification by curative or palliative treatment. This new system appears to be particularly useful for predicting individual HCC prognosis in clinical practice. (Hepatology 2018;67:2215-2225).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Borzio M, Dionigi E, Rossini A, et al. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. Hepatology. 2018. PMID: 29165831. doi:10.1002/hep.29662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。